

Proven long-term effect for Dicot's drug candidate

Press release: Uppsala, August 24, 2021. The pharmaceutical company Dicot now releases results from its latest animal study concluding that the drug candidate LIB-01 has a longer effect on erectile function than other drugs on the market today, and that the effect increases over time. The study outcome is a significant milestone for the LIB-01 project.

As previously reported Dicot is conducting animal studies in collaboration with the French contract laboratory Pelvipharm, where the drug candidate LIB-01's effect on erectile function is tested in both healthy rats and in animal disease models. The results from the tests on healthy rats are now released and the results are promising.

The tests were designed to evaluate the duration of LIB-01's effect on erectile function after the administration of the compound. The erectile responses were observed at one, two and seven days following the dose, and they were compared to erectile responses in control rats that received vehicle only.

The results showed that the longer the delay period between the administration and the erectile function evaluation, the greater were the erectile responses induced by the treatment. This means that the responses were greater when the effect was evaluated after two days compared to after one day, and that it further increased when it was evaluated seven days post administration. The mechanism behind the beneficial impact of increasing delay period as well as the optimal delay period remains to be investigated.

“Long-term effect has been one of the most important factors in developing a new class of potency drugs, so this is truly a breakthrough for our project. Our recent results confirm the early academic studies performed by Dicot's founder professor Jarl Wikberg”, says Göran Beijer, CEO of Dicot.

“There is clearly an unmet medical need for patients suffering from erectile dysfunction with insufficient response to the current medications. We have now established, through repetitive studies, that LIB-01 does have effect and that the duration is at least seven days. I'm therefore confident about the effectiveness of Dicot's drug candidate”, comments professor François Giuliano, co-founder of Pelvipharm.

For further information, please contact:

Göran Beijer CEO

Tel: +46 706 63 60 09

Email: goran.beijer@dicot.se

DICOT

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit www.dicot.se.

This information is such that Dicot AB is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on August 24, 2021.
